InspireMD (NSPR) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 08, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-35731
Entity Registrant Name	InspireMD, Inc.
Entity Central Index Key	0001433607
Entity Tax Identification Number	26-2123838
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6303 Waterford District Drive
Entity Address, Address Line Two	Suite 215
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33126
City Area Code	(888)
Local Phone Number	776-6804
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NSPR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,083,763

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands		Sep. 30, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents		$ 15,818	$ 9,640
Marketable securities		24,584	29,383
Accounts receivable:
Trade, net		1,530	1,804
Other		741	648
Prepaid expenses		1,276	578
Inventory		2,445	2,106
TOTAL CURRENT ASSETS		46,394	44,159
NON-CURRENT ASSETS:
Property, plant and equipment, net		1,946	1,060
Operating lease right of use assets		1,145	1,473
Fund in respect of employee rights upon retirement		996	951
TOTAL NON-CURRENT ASSETS		4,087	3,484
TOTAL ASSETS		50,481	47,643
Accounts payable and accruals:
Trade		1,305	939
Other		5,960	5,081
TOTAL CURRENT LIABILITIES		7,265	6,020
LONG-TERM LIABILITIES-
Operating lease liabilities		682	1,038
Liability for employees’ rights upon retirement		1,183	1,084
TOTAL LONG-TERM LIABILITIES		1,865	2,122
COMMITMENTS AND CONTINGENT LIABILITIES
TOTAL LIABILITIES		9,130	8,142
EQUITY:
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023; 25,719,632 and 21,841,215 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		3	2
Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at September 30, 2024 and December 31, 2023; 1,718 shares issued and outstanding at September 30, 2024 and December 31 2023, respectively	[1]
Additional paid-in capital		285,680	261,000
Accumulated deficit		(244,332)	(221,501)
Total equity		41,351	39,501
Total liabilities and equity		$ 50,481	$ 47,643
[1]Represents an amount less than $1 thousand

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	25,719,632	21,841,215
Common stock, shares outstanding	25,719,632	21,841,215
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,172,000	1,172,000
Preferred stock, shares issued	1,718	1,718
Preferred stock, shares outstanding	1,718	1,718

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
REVENUES	$ 1,810	$ 1,556	$ 5,060	$ 4,444
COST OF REVENUES	1,396	1,118	4,023	3,142
GROSS PROFIT	414	438	1,037	1,302
OPERATING EXPENSES:
Research and development	3,915	2,110	9,941	5,946
Selling and marketing	1,472	876	4,154	2,556
General and administrative	3,489	3,091	11,078	8,135
Total operating expenses	8,876	6,077	25,173	16,637
LOSS FROM OPERATIONS	(8,462)	(5,639)	(24,136)	(15,335)
FINANCIAL INCOME, net:	572	461	1,305	824
NET LOSS	$ (7,890)	$ (5,178)	$ (22,831)	$ (14,511)
NET LOSS PER SHARE - basic	$ (0.16)	$ (0.15)	$ (0.58)	$ (0.69)
NET LOSS PER SHARE - diluted	$ (0.16)	$ (0.15)	$ (0.58)	$ (0.69)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic	48,369,412	33,984,953	39,413,004	21,148,538
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - diluted	48,369,412	33,984,953	39,413,004	21,148,538

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]		Preferred Stock [Member] Series C Convertible Preferred Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 1			[1]	$ 218,977	$ (201,585)	$ 17,393
Balance, shares at Dec. 31, 2022	8,330,918		1,718
Net loss						(14,511)	(14,511)
Issuance of common shares, pre-funded warrants and warrants, net of issuance costs	$ 1				37,533		37,534
Issuance of common shares, pre-funded warrants and warrants, net of issuance costs, shares	10,266,270
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award		[1]			2,841		2,841
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, shares	2,802,975
Balance at Sep. 30, 2023	$ 2			[1]	259,351	(216,096)	43,257
Balance, shares at Sep. 30, 2023	21,400,163		1,718
Balance at Jun. 30, 2023	$ 2			[2]	257,729	(210,918)	46,813
Balance, shares at Jun. 30, 2023	21,192,204		1,718
Net loss						(5,178)	(5,178)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award					1,622		1,622
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, shares	207,959
Balance at Sep. 30, 2023	$ 2			[1]	259,351	(216,096)	43,257
Balance, shares at Sep. 30, 2023	21,400,163		1,718
Balance at Dec. 31, 2023	$ 2			[3]	261,000	(221,501)	39,501
Balance, shares at Dec. 31, 2023	21,841,215		1,718
Net loss						(22,831)	(22,831)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award		[3]			7,792		7,792
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, shares	1,844,078
Exercise of pre-funded warrants								[3]
Exercise of pre-funded warrants, shares	1,728,382
Exercise of Warrants Series H to pre-funded warrants and common stock, net of issuance costs	$ 1				16,853		16,854
Exercise of Warrants Series H to pre-funded warrants and common stock, net of issuance costs, shares	292,996
Issuance of common shares, including at the market offering					35		35
Issuance of common shares, including at the market offering, shares	12,961
Balance at Sep. 30, 2024	$ 3				285,680	(244,332)	41,351
Balance, shares at Sep. 30, 2024	25,719,632		1,718
Balance at Jun. 30, 2024	$ 3			[4]	283,202	(236,442)	46,763
Balance, shares at Jun. 30, 2024	25,196,479		1,718
Net loss						(7,890)	(7,890)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award					2,443		2,443
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, shares	310,200
Exercise of pre-funded warrants								[4]
Exercise of pre-funded warrants, shares	199,992
Issuance of common shares, including at the market offering					35		35
Issuance of common shares, including at the market offering, shares	12,961
Balance at Sep. 30, 2024	$ 3				$ 285,680	$ (244,332)	$ 41,351
Balance, shares at Sep. 30, 2024	25,719,632		1,718
[1]Represents an amount less than $1 thousand[2]Represents an amount less than $1 thousand[3]Represents an amount less than $1 thousand[4]Represents an amount less than $1 thousand

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Payments of stock issuance costs				$ 4,635
Shares restricted stock award, forfeited		9,749	112,382	14,019
Number of pre-funded warrants issued	12,621,090		12,621,090
Proceeds from issuance of common stock			$ 1,000
Market offering costs	$ 1		$ 1
Common Stock [Member]
Common stock shares issued			292,996

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (22,831)	$ (14,511)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	205	171
Gain from sale of property, plant and equipment		(4)
Loss on amounts funded in respect of employee rights upon retirement	21	70
Changes in fair value of marketable securities, net of interest received	(757)	(321)
Change in liability for employees’ rights upon retirement	99	16
Other financial expenses (income)	(8)	72
Change in operating right of use asset and leasing liability	(39)	(39)
Share-based compensation expenses	7,792	2,841
Decrease in interest receivable on short term deposits		171
Changes in operating asset and liability items:
Decrease (increase) in prepaid expenses	(698)	179
Decrease (increase) in trade receivables	274	(11)
Increase in other receivables	(93)	(150)
Increase in inventory	(339)	(225)
Increase (decrease) in trade payables	366	(59)
Increase (decrease) in other payables	890	(399)
Net cash used in operating activities	(15,118)	(12,199)
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in short-term bank deposits		(5,500)
Purchase of property, plant and equipment	(1,091)	(166)
Proceeds from sale of property, plant and equipment		9
Investments in marketable securities	(14,444)	(28,838)
Proceeds from matured marketable securities	20,000
Withdrawal from short-term bank deposits		18,500
Amounts funded in respect of employee rights upon retirement	(66)	(61)
Net cash provided by (used in) investing activities	4,399	(16,056)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants, net of $1,000 issuance costs	16,854
Proceeds from issuance of shares and warrants, net	35	37,534
Net cash provided by financing activities	16,889	37,534
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	8	(72)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	6,178	9,207
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD	9,640	4,632
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	15,818	13,839
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
Acquisition of right-of-use assets by means of lease liabilities		419
Non-cash lease incentive		45
Decrease in right-of-use assets and lease liabilities due to shortening lease term		$ 131

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Statement of Cash Flows [Abstract]
Proceeds from issuance cost of warrants	$ 1,000	$ 1,000

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (7,890)	$ (5,178)	$ (22,831)	$ (14,511)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b51 Arrangement Adopted	false
Non-Rule 10b51 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS a. General InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company markets its products through distributors in international markets, mainly in Europe. b Liquidity The Company has an accumulated deficit as of September 30, 2024, as well as a history of net losses and negative operating cash flows in recent years. The Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company does not have sufficient resources to fund operations for at least the next 12 months. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans include the continued commercialization of the Company’s product and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships and exercise of warrants. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations. c. Risks Related to the Company’s Operations in Israel In October 2023, Israel was attacked by a terrorist organization and entered a state of war. In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization), Israel’s southern border with the Gaza Strip (with the Hamas terrorist organization) and on other fronts from various extremist groups in region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. In addition, Iran recently launched direct attacks on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The Company operations, including its production facility, are located in Israel. Currently, such activities in Israel remain largely unaffected. During the nine and three months ended September 30, 2024, the impact of this war on the Company’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2 - BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements for the year ended December 31, 2023. In the opinion of the company, all adjustments considered necessary for a fair statement of the results of the interim periods reported herein have been included (consisting only of normal recurring adjustments). These condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 5, 2024. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of results that could be expected for the entire fiscal year.

RECENTLY ADOPTED AND ISSUED ACC

RECENTLY ADOPTED AND ISSUED ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2024
Accounting Changes and Error Corrections [Abstract]
RECENTLY ADOPTED AND ISSUED ACCOUNTING PRONOUNCEMENTS	NOTE 3 - RECENTLY ADOPTED AND ISSUED ACCOUNTING PRONOUNCEMENTS Recently adopted accounting pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company adopted the provisions of this update as of January 1, 2024 with no material impact on its consolidated financial statements. Recently issued accounting pronouncement, not yet adopted 1) In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under Accounting Standards Codification (“ASC”) 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures. 2) In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 4 – FAIR VALUE MEASUREMENTS Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS Total Level 1 Level 2 Level 3 As of September 30, 2024 Total Level 1 Level 2 Level 3 Assets: Cash equivalents- Money market funds $ 2,677 $ 2,677 $ - $ - Marketable securities- U.S. government bonds $ 24,584 $ - $ 24,584 $ - Total Level 1 Level 2 Level 3 As of December 31, 2023 ($ in thousands) Total Level 1 Level 2 Level 3 Assets: Cash equivalents- Money market funds $ 7,094 $ 7,094 $ - $ - Cash equivalents $ 7,094 $ 7,094 $ - $ - Marketable securities- U.S. government bonds $ 29,383 $ - $ 29,383 $ - Marketable securities $ 29,383 $ - $ 29,383 $ - The Company’s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The cost of marketable securities as of September 30, 2024, is $ 23,919 The cost of Marketable securities as of December 31, 2023 is $ 28,727

MARKETABLE SECURITIES

MARKETABLE SECURITIES	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
MARKETABLE SECURITIES	NOTE 5 - MARKETABLE SECURITIES The following table sets forth the Company’s marketable securities for the indicated period: SCHEDULE OF MARKETABLE SECURITIES September 30, December 31, 2024 2023 ($ in thousands) U.S. government bonds $ 24,584 $ 29,383 Marketable securities $ 24,584 $ 29,383 The following table summarizes the fair value of the Company’s marketable securities classified by maturity as of September 30, 2024, and December 31, 2023: SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY September 30, December 31, 2024 2023 ($ in thousands) Amounts maturing within one year $ 24,584 $ 24,523 Amounts maturing after one year through two years - 4,860 $ 24,584 $ 29,383 The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the nine months period ended September 30, 2024: SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES Nine months ended September 30, Nine months ended September 30, 2024 2023 ($ in thousands) Balance at beginning of the period $ 29,383 - Additions 14,444 28,838 Maturity (20,000 ) Interest received (217 ) Changes in fair value during the period 974 321 Balance at end of the period 24,584 29,159 The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis.

EQUITY

EQUITY	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
EQUITY	NOTE 6 - EQUITY 1) Exercise of Series H Warrant The Series H Warrants have a term of the earlier of (i) five years Following the announcement on May 28, 2024 of the one year follow up study results from the Company’s C-GUARDIANS pivotal trial, the Series H warrants for the purchase of 12,914,086 292,996 12,621,090 16.9 1 1.3827 1.3826 2) ATM Offering The Company maintains an at-the-market (“ATM”) facility with Piper Sandler & Co. (“Piper”) pursuant to an Equity Distribution Agreement entered into in May 2024. In accordance with the agreement, the Company is entitled, at its sole discretion, to offer and sell through or to Piper Sandler, acting as a sales agent, shares of its common stock having an aggregate offering price of up to $ 17.0 3.0 12,961 35 1 3) During the nine months ended September 30, 2024, the Company issued a total of 1,728,382 1,728,390 200,000 199,992 26,147,323 4) As of September 30, 2024, there were 1,718 7,952 10,997 5) As of September 30, 2024, the Company has outstanding warrants to purchase an aggregate of 40,268,464 SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK Number of Exercise price Expiration date Series F Warrants 433,878 $ 7.4250 June 5, 2025-October 16, 2025 Series G Warrants 1,092,344 $ 10.230 February 8, 2026 Series I Warrants 12,914,078 $ 1.3827 - Series J Warrants 12,914,086 $ 1.3827 - Series K Warrants 12,914,078 $ 1.3827 - Total Warrants 40,268,464 * The Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval from the Food and Drug Administration (“FDA”) for the CGuard Prime Carotid Stent System (135 cm), (B) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 and (C) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begins. During the nine months ended September 30, 2024, a total of 213,458 6) As of September 30, 2024, the Company had 155,000,000 0.0001 150,000,000 5,000,000 7) On September 30, 2024, the compensation committee of the Company’s board of directors of approved the InspireMD, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”) to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual’s entry into employment with the Company. 8) During the nine months ended September 30, 2024, the Company granted 1,944,603 The fair value of the above restricted shares was approximately $ 5.83 9) During the nine months ended September 30, 2024, the Company granted 563,499 The fair value of the above restricted share units was approximately $ 1.77 10) During the nine months ended September 30, 2024, the Company granted to employees and directors options to purchase a total of 761,114 2.44 3.14 In calculating the fair value of the above options, the Company used the following assumptions: dividend yield of 0 5.5 6.5 93.18 119.38 3.93 4.44 The fair value of the above options, using the Black-Scholes option-pricing model, was approximately $ 1.94 11) On April 1, 2024, the Company granted to consultants options to purchase a total of 125,000 2.37 25,000 12,500 12,500 100,000 In calculating the fair value of the above options, the Company used the following assumptions: dividend yield of 0 %; expected volatility ranging from 96.01 %- 100.76 %; and risk-free interest rate ranging from 4.33 %- 4.34 %. The fair value of the above options, using the Black-Scholes option-pricing model, was $ 233,169

RELATED PARTIES TRANSACTIONS

RELATED PARTIES TRANSACTIONS	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTIES TRANSACTIONS	NOTE 7 – RELATED PARTIES TRANSACTIONS During the nine and three months ended September 30, 2024, a member of the immediate family of the CEO provided certain administrative services in connection with the Company’s expansion to the U.S. in the amount of $ 55,000 and $ 25,000 , respectively.

NET LOSS PER SHARE

NET LOSS PER SHARE	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NOTE 8 - NET LOSS PER SHARE Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock, pre-funded warrants and fully vested restricted stock units outstanding during the period. The calculation of diluted net loss per share excludes the effect of potential dilution of share options, warrants, and unvested restricted stocks, unvested restricted stock units and Series C preferred stock as the effect is anti-dilutive. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. For the nine and three-month periods ended September 30, 2024, we had weighted average pre-funded warrants of 19,016,286 26,199,497 The total number of shares of common stock related to outstanding options, warrants, unvested restricted stock, unvested restricted stock units and Series C Preferred Stock excluded from the calculations of diluted loss per share were 48,619,222 59,753,458 This amount includes 3,979,486 3,073,821

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2024
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS	NOTE 9 - FINANCIAL INSTRUMENTS a. Fair value of financial instruments The carrying amounts of financial instruments approximate their fair value either because these amounts are presented at fair value or due to the relatively short-term maturities of such instruments. b. As of September 30, 2024, and December 31, 2023, allowance for expected credit loss was immaterial.

INVENTORY

INVENTORY	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
INVENTORY	NOTE 10- INVENTORY SCHEDULE OF INVENTORIES September 30, December 31, 2024 2023 ($ in thousands) Finished goods $ 68 $ 210 Work in process 557 562 Raw materials and supplies 1,820 1,334 Total inventory $ 2,445 $ 2,106

ACCOUNTS PAYABLE AND ACCRUALS -

ACCOUNTS PAYABLE AND ACCRUALS - OTHER	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUALS - OTHER	NOTE 11 - ACCOUNTS PAYABLE AND ACCRUALS - OTHER SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER September 30, December 31, 2024 2023 ($ in thousands) Employees and employee institutions 2,312 2,188 Accrued vacation and recreation pay 401 287 Accrued expenses 1,437 1,115 Clinical trials accrual 1,078 744 Current Operating lease liabilities 546 557 Other 186 190 Accounts Payable and Accruals - Other 5,960 5,081

DISAGGREGATED REVENUE AND ENTIT

DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES	NOTE 12 - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS 2024 2023 2024 2023 Three months ended Nine months ended 2024 2023 2024 2023 ($ in thousands) Germany 306 209 855 699 Italy 306 328 865 932 Russia 190 250 375 483 Poland 176 122 534 320 Other 832 647 2,431 2,010 Revenues $ 1,810 $ 1,556 $ 5,060 $ 4,444 By principal customers: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS 2024 2023 2024 2023 Three months ended Nine months ended 2024 2023 2024 2023 Customer A 17 % 13 % 17 % 16 % Customer B 11 % 16 % 7 % 11 % Customer C 7 % 13 % 8 % 10 % Customer D 10 % 8 % 9 % 11 % Customer E 10 % 8 % 11 % 7 % Customer 10 % 8 % 11 % 7 %

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS 1) As of the approval date of these financial statements, the Company has issued an aggregate of 197,167 shares of restricted common stock pursuant to the 2024 Inducement Plan and 32,648 2) On October 9, 2024, the Company entered into a lease agreement in Miami, Florida (the “Lease”) for the establishment of its new global headquarters. The Lease has a term of 64 months from the Commencement Date five Under the Lease, the Company will pay the Landlord a security deposit of $ 500 23 3) From October 1, 2024 through the date of the approval of these financial statements, 134,316 341 10

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS	The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS Total Level 1 Level 2 Level 3 As of September 30, 2024 Total Level 1 Level 2 Level 3 Assets: Cash equivalents- Money market funds $ 2,677 $ 2,677 $ - $ - Marketable securities- U.S. government bonds $ 24,584 $ - $ 24,584 $ - Total Level 1 Level 2 Level 3 As of December 31, 2023 ($ in thousands) Total Level 1 Level 2 Level 3 Assets: Cash equivalents- Money market funds $ 7,094 $ 7,094 $ - $ - Cash equivalents $ 7,094 $ 7,094 $ - $ - Marketable securities- U.S. government bonds $ 29,383 $ - $ 29,383 $ - Marketable securities $ 29,383 $ - $ 29,383 $ -

MARKETABLE SECURITIES (Tables)

MARKETABLE SECURITIES (Tables)	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
SCHEDULE OF MARKETABLE SECURITIES	The following table sets forth the Company’s marketable securities for the indicated period: SCHEDULE OF MARKETABLE SECURITIES September 30, December 31, 2024 2023 ($ in thousands) U.S. government bonds $ 24,584 $ 29,383 Marketable securities $ 24,584 $ 29,383
SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY	The following table summarizes the fair value of the Company’s marketable securities classified by maturity as of September 30, 2024, and December 31, 2023: SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY September 30, December 31, 2024 2023 ($ in thousands) Amounts maturing within one year $ 24,584 $ 24,523 Amounts maturing after one year through two years - 4,860 $ 24,584 $ 29,383
SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES	The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the nine months period ended September 30, 2024: SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES Nine months ended September 30, Nine months ended September 30, 2024 2023 ($ in thousands) Balance at beginning of the period $ 29,383 - Additions 14,444 28,838 Maturity (20,000 ) Interest received (217 ) Changes in fair value during the period 974 321 Balance at end of the period 24,584 29,159

EQUITY (Tables)

EQUITY (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK	SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK Number of Exercise price Expiration date Series F Warrants 433,878 $ 7.4250 June 5, 2025-October 16, 2025 Series G Warrants 1,092,344 $ 10.230 February 8, 2026 Series I Warrants 12,914,078 $ 1.3827 - Series J Warrants 12,914,086 $ 1.3827 - Series K Warrants 12,914,078 $ 1.3827 - Total Warrants 40,268,464 * The Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval from the Food and Drug Administration (“FDA”) for the CGuard Prime Carotid Stent System (135 cm), (B) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 and (C) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begins.

INVENTORY (Tables)

INVENTORY (Tables)	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	SCHEDULE OF INVENTORIES September 30, December 31, 2024 2023 ($ in thousands) Finished goods $ 68 $ 210 Work in process 557 562 Raw materials and supplies 1,820 1,334 Total inventory $ 2,445 $ 2,106

ACCOUNTS PAYABLE AND ACCRUALS_2

ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER	SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER September 30, December 31, 2024 2023 ($ in thousands) Employees and employee institutions 2,312 2,188 Accrued vacation and recreation pay 401 287 Accrued expenses 1,437 1,115 Clinical trials accrual 1,078 744 Current Operating lease liabilities 546 557 Other 186 190 Accounts Payable and Accruals - Other 5,960 5,081

DISAGGREGATED REVENUE AND ENT_2

DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS	Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS 2024 2023 2024 2023 Three months ended Nine months ended 2024 2023 2024 2023 ($ in thousands) Germany 306 209 855 699 Italy 306 328 865 932 Russia 190 250 375 483 Poland 176 122 534 320 Other 832 647 2,431 2,010 Revenues $ 1,810 $ 1,556 $ 5,060 $ 4,444
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS	By principal customers: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS 2024 2023 2024 2023 Three months ended Nine months ended 2024 2023 2024 2023 Customer A 17 % 13 % 17 % 16 % Customer B 11 % 16 % 7 % 11 % Customer C 7 % 13 % 8 % 10 % Customer D 10 % 8 % 9 % 11 % Customer E 10 % 8 % 11 % 7 % Customer 10 % 8 % 11 % 7 %

SCHEDULE OF FINANCIAL ASSETS SU

SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 23,919	$ 28,727
Fair Value, Recurring [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	24,584	29,383
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	24,584	29,383
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Fair Value, Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,677	7,094
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,677	7,094
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Cost of marketable securities	$ 23,919	$ 28,727

SCHEDULE OF MARKETABLE SECURITI

SCHEDULE OF MARKETABLE SECURITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Marketable securities	$ 24,584	$ 29,383	$ 29,159
US Government Agencies Debt Securities [Member]
Marketable Securities [Line Items]
Marketable securities	$ 24,584	$ 29,383

SCHEDULE OF FAIR VALUE OF MARKE

SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Amounts maturing within one year	$ 24,584	$ 24,523
Amounts maturing after one year through two years		4,860
Marketable securities	$ 24,584	$ 29,383	$ 29,159

SCHEDULE OF CHANGES IN FAIR VAL

SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Balance at beginning of the period	$ 29,383
Additions	14,444	28,838
Maturity	(20,000)
Interest received	(217)
Changes in fair value during the period	974	321
Balance at end of the period	$ 24,584	$ 29,159

SCHEDULE OF ISSUANCE OF WARRANT

SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Class of Stock [Line Items]
Total Warrants	40,268,464
Series F Warrants [Member]
Class of Stock [Line Items]
Total Warrants	433,878
Weighted average exercise price | $ / shares	$ 7.4250
Expiration date	June 5, 2025-October 16, 2025
Series G Warrants [Member]
Class of Stock [Line Items]
Total Warrants	1,092,344
Weighted average exercise price | $ / shares	$ 10.230
Expiration date	Feb. 08, 2026
Series I Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,078
Weighted average exercise price | $ / shares	$ 1.3827
Expiration date		[1]
Series J Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,086
Weighted average exercise price | $ / shares	$ 1.3827
Expiration date		[1]
Series K Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,078
Weighted average exercise price | $ / shares	$ 1.3827
Expiration date		[1]
[1]The Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval from the Food and Drug Administration (“FDA”) for the CGuard Prime Carotid Stent System (135 cm), (B) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 and (C) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begins.

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)					3 Months Ended	9 Months Ended
		May 28, 2024	Apr. 01, 2024	May 15, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Class of Stock [Line Items]
Warrants to purchase common stock					40,268,464	40,268,464
Total gross proceeds						$ 1,000,000
Preferred stock stated value	[1]
Warrants expired						213,458,000
Capital stock shares authorized					155,000,000	155,000,000
Capital stock par value					$ 0.0001	$ 0.0001
Common stock shares authorized					150,000,000	150,000,000		150,000,000
Restricted Stock [Member] | Employees and Directors [Member]
Class of Stock [Line Items]
Shares granted						1,944,603
Fair value of shares granted						$ 5,830,000
Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]
Class of Stock [Line Items]
Shares granted						563,499
Fair value of shares granted						$ 1,770,000
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member]
Class of Stock [Line Items]
Option granted to consultants						761,114
Expected dividend rate			0%			0%
Expected volatility, minimum			96.01%			93.18%
Expected volatility, maximum			100.76%			119.38%
Fair value stock option price			$ 233,169			$ 1,940,000
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member] | Minimum [Member]
Class of Stock [Line Items]
Stock option exercise price						$ 2.44
Expected term						5 years 6 months
Risk-free interest rate, maximum			4.33%			3.93%
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member] | Maximum [Member]
Class of Stock [Line Items]
Stock option exercise price						$ 3.14
Expected term						6 years 6 months
Risk-free interest rate, maximum			4.34%			4.44%
Share-Based Payment Arrangement, Option [Member] | Consultants [Member]
Class of Stock [Line Items]
Option granted to consultants			125,000
Stock option exercise price			$ 2.37
Number of options vesting in period			25,000
Share-Based Payment Arrangement, Option [Member] | Consultants [Member] | Performance Conditions [Member]
Class of Stock [Line Items]
Number of options vesting in period			100,000
Share-Based Payment Arrangement, Option [Member] | Consultants [Member] | First Year Vesting Period [Member]
Class of Stock [Line Items]
Number of options vesting in period			12,500
Share-Based Payment Arrangement, Option [Member] | Consultants [Member] | Second Year Vesting Period [Member]
Class of Stock [Line Items]
Number of options vesting in period			12,500
Pre Funded Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common stock					26,147,323	26,147,323
Issuance of shares		12,621,090
Shares issues						200,000
Common Stock [Member]
Class of Stock [Line Items]
Issuance of shares							10,266,270
Shares issues					199,992	1,728,382
Warrants purchased, shares						1,728,390
Stock exercised cashless, shares						199,992
Warrant [Member] | At The Market Offering [Member]
Class of Stock [Line Items]
Warrants to purchase common stock					40,268,464	40,268,464
Preferred Stock Blank Check [Member]
Class of Stock [Line Items]
Preferred stock shares authorized					5,000,000	5,000,000
Series H Warrant [Member]
Class of Stock [Line Items]
Warrant term					5 years	5 years
Warrants to purchase common stock		12,914,086
Issuance of shares		292,996
Warrants exercise				$ 16,900,000
Placement agent fees				$ 1,000,000
Series H Warrant [Member] | Pre Funded Warrants [Member]
Class of Stock [Line Items]
Warrants exercise price		$ 1.3826
Series H Warrant [Member] | Common Stock [Member]
Class of Stock [Line Items]
Warrants exercise price		$ 1.3827
ATM Offering [Member] | Equity Distribution Agreement [Member]
Class of Stock [Line Items]
Aggregate offering price					$ 17	$ 17
Commission percentage						3%
Common stock, shares sold						12,961
Total gross proceeds						$ 35,000
Total fees						$ 1,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding					1,718	1,718		1,718
Preferred stock convertible shares issuable					7,952	7,952
Preferred stock stated value					$ 10,997	$ 10,997
Preferred stock shares authorized					1,172,000	1,172,000		1,172,000
[1]Represents an amount less than $1 thousand

RELATED PARTIES TRANSACTIONS (D

RELATED PARTIES TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Chief Executive Officer [Member]
Related Party Transaction, Amounts of Transaction	$ 25,000	$ 55,000

NET LOSS PER SHARE (Details Nar

NET LOSS PER SHARE (Details Narrative) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Weighted average prefunded warrants	26,199,497	19,016,286
Unvested restricted stock	3,979,486	3,979,486	3,073,821
Series C Preferred Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Diluted loss per share		48,619,222	59,753,458

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Finished goods	$ 68	$ 210
Work in process	557	562
Raw materials and supplies	1,820	1,334
Total inventory	$ 2,445	$ 2,106

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Employees and employee institutions	$ 2,312	$ 2,188
Accrued vacation and recreation pay	401	287
Accrued expenses	1,437	1,115
Clinical trials accrual	1,078	744
Current Operating lease liabilities	546	557
Other	186	190
Accounts Payable and Accruals - Other	$ 5,960	$ 5,081

SCHEDULE OF REVENUES ATTRIBUTED

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 1,810	$ 1,556	$ 5,060	$ 4,444
GERMANY
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	306	209	855	699
ITALY
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	306	328	865	932
RUSSIAN FEDERATION
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	190	250	375	483
POLAND
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	176	122	534	320
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 832	$ 647	$ 2,431	$ 2,010

SCHEDULE OF REVENUES ATTRIBUT_2

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details) - Sales [Member] - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Customer A [Member]
Revenue, Major Customer [Line Items]
Customer	17%	13%	17%	16%
Customer B [Member]
Revenue, Major Customer [Line Items]
Customer	11%	16%	7%	11%
Customer C [Member]
Revenue, Major Customer [Line Items]
Customer	7%	13%	8%	10%
Customer D [Member]
Revenue, Major Customer [Line Items]
Customer	10%	8%	9%	11%
Customer E [Member]
Revenue, Major Customer [Line Items]
Customer	10%	8%	11%	7%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($) $ in Thousands			1 Months Ended	9 Months Ended
	Oct. 09, 2024	Sep. 30, 2024	Nov. 12, 2024	Sep. 30, 2024
Subsequent Event [Line Items]
Gross proceeds				$ 1,000
Subsequent Event [Member] | ATM Offering [Member]
Subsequent Event [Line Items]
Number of shares sold			134,316
Gross proceeds			$ 341
Total fees			$ 10
2024 Inducement Plan Member]
Subsequent Event [Line Items]
Restricted common stock shares		32,648
2024 Inducement Plan Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		197,167
Lease Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Lease description	The Lease has a term of 64 months from the Commencement Date
Lease extension term	5 years
Security deposit	$ 500
Base rent	$ 23